You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Pfizer
since
auto-detected in 83 stories
12 days ago
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
35 days ago
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth ⊕
Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
78 days ago
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss ⊖
Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
4 months ago
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data ⊕⊕
Pfizer made one thing clear this week: It's officially back in the obesity race.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook ○
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more ○
These are the stocks posting the largest moves in early trading.
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial ⊕
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
S&P 500 futures climb after index starts February trading on a winning note: Live updates ⊕
Investors this week are digesting more than 100 S&P 500 companies posting earnings results. AMD and Pfizer are among those expected to report on Tuesday.
U.S. names HIV, arthritis drugs for next Medicare price talks ○
found
The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz.
What obesity drugmakers see next in the market: More pills, easier access and drug combinations ⊕
found
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.